Findings establish CAR-M as a potential new immune-reset modality with improved safety over in vivo CAR-T approachesCAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, Inc., a biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback